Pharmos Corp

Pharmos — Shareholder Meeting (October 2006)

26 slides from Pharmos's shareholder meeting presentation, Oct 26, 2006

  1. Slide 1: Annual Shareholders Meeting October 2006

    Slide 1: Annual Shareholders Meeting October 2006

    Annual Shareholders Meeting October 2006 PHARMOS

  2. Slide 2: Safe Harbor Statement

    Slide 2: Safe Harbor Statement

    Safe Harbor Statement Statements made in this presentation related to the business outlook and future financial performance of the Company, to the prospective market penetration of its drug products, to the development and commercialization of the Company's pipeline products, to the potential from t

  3. Slide 3: Last Year

    Slide 3: Last Year

    Last Year Objective: Broaden product pipeline by acquiring company or products with reliable clinical data in specific areas of interest Advance internal CB2 platform & Nano delivery project. Strengthen management

  4. Slide 4: The Vela Acquisition Summary

    Slide 4: The Vela Acquisition Summary

    The Vela Acquisition Summary Fulfills strategic objective / excellent fit Expands pipeline – later stage clinical drugs Complements focus on pain /inflammation Dextofisopam – successful Phase 2a in IBS Two additional later-stage assets Tianeptine – strong follow-on for IBS VPI-013 – Phase 2 asset fo

  5. Slide 5: The New Pharmos Pipeline

    Slide 5: The New Pharmos Pipeline

    The New Pharmos Pipeline * Nano-Tech emulsion delivery Preclinical Phase 1 Phase 2 Phase 3 Dextofisopam (Vela) IBS Tianeptine (Vela) PRS-XXX/ CB2 Agonist Autoimmune Neuropathic Pain Topical NSAID’s * Nano Diclofenac for OA Nano Ketorolac for OA Cannabinor (CB2) IV Nociceptive Pain Neuropathic Pain I

  6. Slide 6: IBS Overview

    Slide 6: IBS Overview

    IBS Overview PHARMOS

  7. Slide 7: IBS – A Significant Underserved Market

    Slide 7: IBS – A Significant Underserved Market

    IBS – A significant Underserved Market Estimated >10% prevalence in US* (~1/3 significant) Women to men 3 to 1 Responsible for 3.7 million annual visits to GI specialists* Patients unsatisfied with current treatment * in 2004 * Saito et al. The epidemiology of irritable bowel syndrome in North Ameri

  8. Slide 8: IBS: A Significant Underserved Market

    Slide 8: IBS: A Significant Underserved Market

    IBS: A Significant Underserved Market Diarrhea- Predominant 36% Constipation- Predominant 31% Alternating Diarrhea and Constipation 33% 5-HT 3 Antagonist Lotronex ® (GSK) • Sales: $10 - 12 million* 5-HT 4 Agonist Zelnorm ® (Novartis) • Sales: $370 - 380 million* * Projected 2006 Dextofisopam

  9. Slide 9: Dextofisopam

    Slide 9: Dextofisopam

    Dextofisopam PHARMOS

  10. Slide 10: Dextofisopam: Leading Asset in Development for IBS

    Slide 10: Dextofisopam: Leading Asset in Development for IBS

    Dextofisopam: Leading Asset in Development for IBS Dextofisopam Potentially normalizes GI dysmotility Binds to receptors in brain areas modulating GI function Also has broad local anti-inflammatory properties Expectation for good safety profile Good proprietary position Positive Phase 2 data

  11. Slide 11: Dextofisopam: Phase 2a Study Design

    Slide 11: Dextofisopam: Phase 2a Study Design

    Dextofisopam: Phase 2a Study Design Double-blind, US study (33 sites) 141 men and women with diarrhea-predominant or alternating IBS 200 mg BID dextofisopam or placebo for 12 weeks Primary endpoint * : “adequate relief” Weekly… Patient friendly, global measure • FDA accepted measure Secondary endpoi

  12. Slide 12: Dextofisopam Phase 2a Study Results: Summary

    Slide 12: Dextofisopam Phase 2a Study Results: Summary

    Dextofisopam Phase 2a Study Results: Summary Positive effect on primary efficacy endpoint 32% advantage vs. placebo Statistically significant (p = 0.033) Positive effect on key secondary efficacy endpoints Dextofisopam decreased stool frequency and improved (hardened) stool consistency in patients w

  13. Slide 13: Synthetic Cannabinoid Agonists

    Slide 13: Synthetic Cannabinoid Agonists

    Synthetic Cannabinoid Agonists PHARMOS

  14. Slide 14: Cannabinoid Receptor Agonists

    Slide 14: Cannabinoid Receptor Agonists

    Cannabinoid Receptor Agonists CB1 R – primarily in brain & nerves Psychoactive effects Pain Satiety (obesity) CB2 R – primarily in immune related cells Immune modulation (multiple sclerosis, rheumatoid arthritis and IBD, atherosclerosis) Pain ( neuropathic pain) Bone formation (osteoporosis) Objecti

  15. Slide 15: CB2 Market Opportunity

    Slide 15: CB2 Market Opportunity

    CB2 Market Opportunity Pain – large market (> $US 15B annual sales) Significant growth potential. Neuropathic pain – underserved, search for new approach (non- opioid) Multiple Sclerosis – large market potential Need for new effective, safe and orally delivered drugs Other addressable indications Rh

  16. Slide 16: Cannabinor Clinical Trials

    Slide 16: Cannabinor Clinical Trials

    Cannabinor Clinical Trials Phase 2a – Proof of principal pain trials * underway (IV formulation) Nociceptive (third molar extraction) 100 patients Neuropathic (capsaicin-induced) 24 subjects Phase 1 trial completed – well tolerated Oral formulation developed * Establish human therapeutic window

  17. Slide 17: Cannabinor – Oral Formulation Program

    Slide 17: Cannabinor – Oral Formulation Program

    Cannabinor – Oral Formulation Program Objective: develop product for chronic use Potential indications Neuropathic pain Autoimmune diseases Formulation achieved > 25% bioavailability in pigs Ongoing 28 days tox study in monkeys near completion Clinical Phase 1 trial initiation targeted 1Q2007 Clinic

  18. Slide 18: CB2 Specific Pipeline

    Slide 18: CB2 Specific Pipeline

    CB2 Specific Pipeline PRS-XXX – Objective: Improved Profile Robust efficacy in animal models of pain ( moderate and neuropathic pain) and autoimmune diseases (remitting-relapsing multiple sclerosis and inflammatory bowel disease ) CB1 safety: CB1 side effects (tetrad) were not observed at the highes

  19. Slide 19: CB2 Specific Pipeline

    Slide 19: CB2 Specific Pipeline

    CB2 Specific Pipeline PRS YYY Lead optimization - ongoing Improved drug-like properties CB2 R activation with low CB1 activity Targeted for chronic indications (osteoporosis & atherosclerosis) No safety issues noted in pre-clinical studies

  20. Slide 20: Nano Based Topical NSAID

    Slide 20: Nano Based Topical NSAID

    Nano Based Topical NSAID PHARMOS

  21. Slide 21: Nano Based topical NSAID

    Slide 21: Nano Based topical NSAID

    Nano Based topical NSAID Osteoarthritis (inflammation of the joints) and other tissue inflammation, very prevalent (30 million in US) and growing with age About 25% are not treated because of side effects (GI & cardio) Pharmos Nano delivery technology aimed to target drug directly to tissue, therefo

  22. Slide 22: Nano Based topical NSAID

    Slide 22: Nano Based topical NSAID

    Nano Based topical NSAID 3% Diclofenac Nano Emulsion formulation developed Tissue distribution tested in animals demonstrating tissue targeting concept Phase 1 clinical trial to test safety – ongoing Plan to test efficacy in patients (Phase 2) Expect lower regulatory risk with well known NSAID

  23. Slide 23: Company Highlights

    Slide 23: Company Highlights

    Company Highlights PHARMOS

  24. Slide 24: Pharmos Trading/Financial Highlights

    Slide 24: Pharmos Trading/Financial Highlights

    Pharmos Trading/Financial Highlights NASDAQ: PARS Market capitalization: $39.1 million Recent price: $2.05 (10/23/06) 52-week high/low: $2.93 - 1.55 Financial (Pre-acquisition): 19.1 million shares outstanding (plus 6.5 million shares to Vela SH) $39.4 million cash/short-term investments (as of 30 J

  25. Slide 25: Pharmos Investment Summary

    Slide 25: Pharmos Investment Summary

    Pharmos Investment Summary Balanced portfolio Early and later-stage products Dextofisopam – strong Phase 2a IBS data Two cannabinor Phase 2a pain studies [in progress] Progress in building CB2R agonist pipeline Building leadership positions in IBS/CB2

  26. Slide 26: Annual Shareholders Meeting October 2006

    Slide 26: Annual Shareholders Meeting October 2006

    Annual Shareholders Meeting October 2006

Source: SEC EDGAR · 8-K filed Oct 26, 2006

More decks from Pharmos Corp